Clinical trials: Virus Diseases
Infections, Papillomavirus
A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females
A phase I, open label, single-centre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV -16/18 L1 VLP AS04 vaccine (GSK 580299, Cervarix TM), administered intramuscularly according to a 0, 1…
- Trial name
- NCT00549900
- Testing
- GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Vulvar Cancer
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04422366
- Testing
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL®
- Where
- China
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Herpes Zoster
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 69 years of…
- Trial name
- NCT06375512
- Testing
- HZ Vaccine (IN001), Shingrix
- Where
- 3 sites in United States, Australia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd
Hepatitis C Infection
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients
The purpose of this study is to identify at least 1 dose of daclatasvir that is safe, well tolerated, and efficacious when combined with peginterferon-alfa and ribavirin for the treatment of hepatitis C virus genotype 1 in…
- Trial name
- NCT01016912
- Testing
- BMS-790052, Peginterferon alfa-2b, Ribavirin
- Where
- 6 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Bristol-Myers Squibb
Infections, Respiratory, Fever
Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals
Operational project to compare clinician collected nasopharyngeal (NP) samples to patient-obtained tongue, nasal and mid-turbinate (MT) samples in the detection of SARS-CoV-2 in an outpatient clinic setting
- Conditions
- Infections, Respiratory, Fever, Cough
- Trial name
- NCT04321369
- Testing
- Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals
- Where
- United States
- Volunteers
- 530 people
- Sponsor
- UnitedHealth Group
HIV/AIDS
Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
The primary objectives are to assess the antiviral activity, clinical safety and tolerability parameters of albuvirtide/3BNC117 combination therapy in reducing HIV-1 viral load during the 1-week induction period treatment period.
- Trial name
- NCT04560569
- Testing
- Albuvirtide, 3BNC117 Antibody
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Frontier Biotechnologies Inc.
COVID-19
Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above
This is a randomized, blinded, positive-controlled study to evaluate the immunogenicity and safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, in population aged 18 years old and above（negative antibody against…
- Trial name
- NCT05663086
- Testing
- One dose group, Two doses group, Aged 18-59 years
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Chronic Hepatitis C
Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies
The primary objective of this study is to assess changes in alanine aminotransferase (ALT) in hepatitis C virus (HCV)-infected subjects given daily doses of JKB-122 for 3 months who have been nonresponsive to, intolerable to, or…
- Trial name
- JKB122 (NCT02293941)
- Testing
- JKB-122 5mg, JKB-122 15mg, JKB-122 35mg
- Where
- 14 sites in Taiwan
- Volunteers
- 54 people
- Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
The purpose of the study is to evaluate the safety and tolerability of B019 in subjects.
- Trial name
- NCT06927466
- Testing
- B019
- Where
- 8 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Common Cold
Iota-Carrageenan Nasal Spray in Common Cold
The aim of this clinical trial is to investigate the effect of Iota-Carrageenan treatment on cold symptoms. The effect of treatment on the duration of the cold and the patients viral load plus cytokine level indicating the…
- Trial name
- NCT01944631
- Testing
- Iota-Carrageenan
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Boehringer Ingelheim
Tetanus, Hepatitis B
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants
This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083 vaccine co-administered with Prevenar 13® at 2, 4 and 12 months of age and with Rotarix™ at 2 and 4 months of age.
- Conditions
- Tetanus, Hepatitis B, Haemophilus Influenzae Type b, Poliomyelitis
- Trial name
- NCT01090453
- Testing
- GSK2202083A vaccine, Prevenar 13®, Infanrix hexa™
- Where
- 34 sites in Canada, France and 1 more
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in subjects' ≥ 50 years of age (YOA) who previously have had Herpes Zoster (HZ).
- Trial name
- NCT01827839
- Testing
- Herpes Zoster vaccine (GSK1437173A)
- Where
- 4 sites in Canada, Russia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hand, Foot, and Mouth Disease (HFMD), Enterovirus 71 Infection
Bridging Clinical Trial of EV71 Vaccine in Vietnamese Children
The purpose of this study is to evaluate the immunogenicity and safety of an inactivated Enterovirus Type 71 (EV71) vaccine, manufactured by Sinovac, in healthy Vietnamese children aged 6 to 71 months.
- Trial name
- NCT07793175
- Testing
- EV71 vaccine
- Where
- Vietnam
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Common Cold
Effect of Paracetamol on the Common Cold
The aim of this study is to subjectively assess symptoms in subjects suffering from the common cold following a single dose of paracetamol hot drink compared to paracetamol tablet
- Trial name
- NCT01277081
- Testing
- Paracetamol hot drink, Paracetamol tablets
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
COVID-19
A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19
A Phase 3 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
- Trial name
- NCT05758519
- Testing
- QLS1128
- Where
- China
- Volunteers
- 1,220 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hepatitis B
Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine
The purpose of this study is to find out if a new investigational hepatitis B virus vaccine, HEPLISAV™, is safe and effective compared with Engerix-B® vaccine in subjects 11-55 years old.
- Trial name
- NCT00435812
- Testing
- Engerix-B
- Where
- 18 sites in Canada, Germany
- Volunteers
- 2,428 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
HIV Infections
An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots
This study will assess the distribution of a microbicidal gel in the vagina and confirm the presence of bare spots. MRIs will be done with and without the addition of the MRI contrast Gadolinium to the microbicide in order to…
- Trial name
- NCT00214812
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Biosyn
COVID-19
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19
Randomized open-label multicenter parallel-group study of efficacy and safety of TL-FVP-t vs. standard of care therapy in patients with mild to moderate coronavirus disease (SARS-CoV-2/COVID-19)
- Trial name
- NCT04501783
- Testing
- Favipiravir, Standard of care (SOC), standard concomitant therapy
- Where
- 10 sites in Russia
- Volunteers
- 168 people
- Sponsor
- R-Pharm
Hepatitis B
Phase Ia/Ib Trial of SCTA02A Injection in Healthy Adults and Patients With Chronic Hepatitis B
Study SCTA02A-A101 is designed to assess the safety, tolerability and pharmacokinetics of SCTA02A in healthy volunteers and participants with chronic hepatitis B virus infection.
- Trial name
- NCT07903831
- Testing
- SCTA02A
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.